S63845: Precision Small Molecule MCL1 Inhibitor for Apoptosis Research

Executive Summary: S63845 is a highly selective inhibitor of MCL1, a pivotal anti-apoptotic BCL-2 family protein implicated in cancer cell survival (König et al., 2024). It demonstrates sub-nanomolar binding affinity (KD = 0.19 nM) and strong inhibitory potency (Ki < 1.2 nM) for human MCL1 (APExBIO). S63845 triggers BAX/BAK-dependent mitochondrial apoptosis, resulting in robust cell death in multiple myeloma, lymphoma, CML, and AML cell lines. In vivo, S63845 achieves dose-dependent tumor regression and complete remission in mouse xenograft models. Its high selectivity, solubility profile, and compatibility with caspase-dependent apoptosis assays establish S63845 as a reference compound for studying intrinsic apoptotic mechanisms.

Biological Rationale

Apoptosis is a regulated form of programmed cell death with two principal pathways: extrinsic (death receptor-mediated) and intrinsic (mitochondrial). Cancer cells frequently evade apoptosis by upregulating anti-apoptotic proteins, notably MCL1, a member of the BCL-2 family (König et al., 2024). MCL1 inhibits pro-apoptotic proteins BAK and BAX, thereby blocking mitochondrial outer membrane permeabilization (MOMP) and downstream caspase activation. Overexpression of MCL1 is observed in diverse hematological malignancies and solid tumors, correlating with resistance to chemotherapeutic agents and poor prognosis (BAX Inhibitor, 2024). Targeted inhibition of MCL1 restores the apoptotic threshold, making it a prime target for anti-cancer drug development.

Mechanism of Action of S63845

S63845 is a small molecule that binds directly and selectively to the BH3-binding groove of human MCL1 (KD = 0.19 nM; Ki < 1.2 nM; buffer: PBS, 25°C), displacing endogenous pro-apoptotic partners such as BAK and BAX (APExBIO). Disruption of the MCL1–BAK/BAX interaction enables BAX/BAK oligomerization and mitochondrial outer membrane permeabilization. This cascade leads to the release of cytochrome c, activation of caspase-9, subsequent caspase-3/7 activation, phosphatidylserine (PS) externalization, PARP cleavage, and apoptosis. S63845’s selectivity profile spares other BCL-2 family proteins, reducing off-target effects (PHA-793887, 2024). The compound is ineffective in cells lacking functional BAX/BAK or in those relying on non-MCL1 anti-apoptotic mechanisms.

Evidence & Benchmarks

• S63845 binds human MCL1 with KD = 0.19 nM and Ki < 1.2 nM at 25°C in PBS (APExBIO).
• In vitro, S63845 induces apoptosis in multiple myeloma, lymphoma, CML, and AML cell lines with IC50 values in the low nanomolar/sub-micromolar range (cell culture, 37°C, 5% CO2) (König et al., 2024).
• S63845 activates BAX/BAK-dependent mitochondrial apoptosis, as confirmed by cytochrome c release and caspase-3/7 activation assays (PHA-793887, 2024).
• In immunocompromised mice with human multiple myeloma xenografts (H929, AMO1), intravenous S63845 (dose: 25–50 mg/kg, 3× weekly) achieves >100% tumor growth inhibition and complete remission in a significant subset (in vivo, NOD/SCID mice) (APExBIO).
• Combination of S63845 with extrinsic apoptosis activators (e.g., FLIPinB, death ligands) enhances complex II assembly and cell death in pancreatic and hematological cancer models (König et al., 2024).

For a systems-level perspective on S63845’s role in dissecting mitochondrial and extrinsic death pathways, see this article (this article updates with recent in vivo benchmarks and combination strategies).

Applications, Limits & Misconceptions

S63845 is optimized for research on BCL-2 family protein inhibition, mitochondrial apoptotic pathway activation, and combinatorial apoptosis modulation. It is widely used in:

• Hematological cancer research (multiple myeloma, lymphomas, CML, AML).
• Mechanistic studies of BAX/BAK-dependent apoptosis and caspase-dependent cell death.
• Development and validation of combinatorial anti-tumor strategies targeting both intrinsic and extrinsic pathways (Survivin.net, 2024; this article clarifies combinatorial strategies and translational applications).

Common Pitfalls or Misconceptions

• S63845 is not effective in MCL1-independent cancer models: Its activity strictly depends on MCL1 dependency (no apoptosis in BCL-2/BCL-XL-dependent lines) (APExBIO).
• It cannot induce apoptosis in BAX/BAK-deficient cells: Absence of these effectors abrogates the mitochondrial pathway (PHA-793887, 2024).
• S63845 is not intended for diagnostic or therapeutic use in humans: It is for scientific research only (APExBIO).
• Incorrect solvent use impairs performance: S63845 is insoluble in water; always use DMSO or methanol for stock solutions (APExBIO).
• Stock instability at higher temperatures or prolonged storage: Store below -20°C and avoid repeated freeze-thaw cycles (APExBIO).

Workflow Integration & Parameters

S63845 (APExBIO SKU A8737) is supplied as a lyophilized powder. For optimal solubility, prepare stock solutions in DMSO (≥41.45 mg/mL) or methanol (≥20 mg/mL); warm gently and sonicate if needed. Avoid aqueous solutions. Store aliquots below -20°C and use promptly after thawing to limit degradation. Typical working concentrations for cell-based assays range from 10 nM to 1 μM, depending on cell line sensitivity and experimental design. For in vivo studies, intravenous administration (25–50 mg/kg, 3×/week) in immunocompromised mice is validated (APExBIO). For assay-specific guidance, see this protocol article (this article provides scenario-driven practical integration advice, extending the present mechanistic overview).

Conclusion & Outlook

S63845 serves as a gold-standard small molecule MCL1 inhibitor for the mechanistic dissection of mitochondrial apoptosis and combinatorial anti-cancer strategies. Its selectivity, potency, and reproducibility in both in vitro and in vivo models enable robust, hypothesis-driven studies of cell death networks. Continued research on dual targeting of MCL1 and extrinsic apoptosis regulators (e.g., c-FLIPL) is expected to advance next-generation therapeutic discovery (König et al., 2024). For full technical details and ordering, refer to the S63845 product page (APExBIO).